Publications by authors named "Richard Woessner"

26Publications

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.

Nat Commun 2018 11 2;9(1):4583. Epub 2018 Nov 2.

Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-06949-w
Publisher Site
http://dx.doi.org/10.1038/s41467-018-06949-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214970PMC
November 2018

Inhibition of with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity.

Clin Cancer Res 2017 Apr 19;23(7):1771-1784. Epub 2016 Oct 19.

Cell & Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381521PMC
April 2017

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.

Expert Opin Ther Pat 2017 Feb 7;27(2):127-143. Epub 2016 Nov 7.

c AstraZeneca, Oncology iMED , Waltham , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2017.1252753DOI Listing
February 2017

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.

Expert Opin Ther Pat 2017 Feb 4;27(2):145-161. Epub 2016 Nov 4.

c AstraZeneca, Oncology iMED , Waltham , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2017.1252754DOI Listing
February 2017

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.

Cancer Biol Ther 2011 Nov 1;12(9):788-96. Epub 2011 Nov 1.

Cell Biology, Array BioPharma, Inc., Boulder, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.12.9.17673DOI Listing
November 2011

Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.

Mol Cancer Ther 2010 Jul 22;9(7):2046-56. Epub 2010 Jun 22.

Translational Oncology, Array BioPharma, Inc., Boulder, Colorado 80301, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0033DOI Listing
July 2010

ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.

Anticancer Res 2009 Nov;29(11):4373-80

Department of Pharmacology, Array BioPharma Inc., Boulder, CO 80301, USA.

View Article

Download full-text PDF

Source
November 2009

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

J Transl Med 2009 Jul 20;7:63. Epub 2009 Jul 20.

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://translational-medicine.biomedcentral.com/articles/10.
Publisher Site
http://dx.doi.org/10.1186/1479-5876-7-63DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719595PMC
July 2009